Researchers identify a treatment for a rare bone loss disorder that might also lead to help for aging brittle bones
A possible ‘first-line’ treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Hajdu-Cheney syndrome is a rare genetic disease that leads to severe osteoporosis and developmental defects, including the reabsorption of bones in the hands and feet. The disease is associated with mutations in a particular gene, called NOTCH2, which codes for proteins involved with bone maintenance. The NOTCH2 proteins usually help balance destruction and construction essential for bone maintenance and repair. Mutations associated with Hajdu-Cheney syndrome upset that balance, but the exact mechanisms causing bone resorption have not been well understood.
Now, through a series of detailed tests, molecular biologist Hiroyuki Inuzuka and his colleagues have worked out the specific molecular pathway that results in Hajdu-Cheney syndrome.
They found that this particular NOTCH2 mutation does not maintain normal NOTCH2 protein abundance, with the help of another protein, called FBW7. To discover this, the researchers knocked out the gene for Fbw7 in the bones of mice. Without the gene and resulting protein, the mice had severe osteoporosis, much like people with Hajdu-Cheney syndrome — indicating that FBW7 is the primary regulator of this system.
They further determined that in humans with Hajdu-Cheney syndrome, the FBW7 protein was unable to bind to NOTCH2 proteins because the binding spot is missing in osteoclasts. This mutation allows the osteoclasts to over-operate, breaking down too much bone tissue.
The researchers were able to reverse bone loss in the knock-out mice with the elevated NOTCH2 by giving them a medication that blocks osteoclast formation. They tried several different treatments, including a chemical compound called DAPT that was particularly effective. DAPT has been shown to help with osteoarthritis by inhibiting function of NOTCH proteins in other studies. Using DAPT as well as Zoledronic acid, a common medication for osteoporosis, “may become a first-line treatment for Hadju-Cheney syndrome,” the researchers conclude in their study.
“By clearly identifying the relationship between FBW7 and NOTCH2 proteins, we have identified potential therapeutic targets for patients with rare bone diseases as well as much more widespread age-related osteoporosis,” said Inuzuka.
Learn more: Reversing severe bone loss
The Latest on: Bone loss
via Google News
The Latest on: Bone loss
- Trial questions benefits of organic nitrates for bone healthon May 6, 2020 at 12:55 am
Several clinical trials have reported beneficial effects of organic nitrates on bone health, which could lead to a reduced risk of fractures. Some of these trials have been retracted because of ...
- Let's Talk About Bone Fractures Due to Osteoporosison April 30, 2020 at 1:03 pm
A bone break is often a sudden, painful indicator of osteoporosis. We explain what leads to a break, and how fractures are treated.
- The Renal-Bone Axis and ART in Adolescents and Elderly With HIVon April 30, 2020 at 8:33 am
Particular antiretroviral therapy regimens may decrease bone mass density in both adolescents and older people living with HIV.
- Bone Mineral Density and Microarchitecture Changes During Pregnancyon April 30, 2020 at 8:25 am
There are changes in maternal bone mineral density and microarchitecture during pregnancy that exceed the natural age-related changes in women.
- Bone Graft and Substitutes Market Size Worth USD 4.7 Billion at a 5.5% CAGR By 2027 | Future Trends, Regional Insights and Global Industry Trendson April 30, 2020 at 5:47 am
Bone grafting is preferred for the treatment of sinus lift, ridge augmentation, fracture repair, nerve repositioning, and dental implantation. Trauma and accident can lead to bone damage. Therefore, ...
- Prevention of Bone Loss and Management of Fracture Risk in HIV-infected Individualson April 27, 2020 at 5:00 pm
BMD assessment should be repeated in approximately 3 years' time to assess if there has been any bone loss. For a summary of this case, see Box 4. What Investigations Are Indicated Regarding Her ...
- Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritison April 27, 2020 at 7:23 am
Adeno-associated virus type 2 encoding the prolactin fragment vasoinhibin (AAV2 vasoinhibin) reduces joint inflammation and bone loss in antigen-induced arthritis in mice by inhibiting pannus ...
- UB oral biology researchers receive a combined $6.6 million to study gum disease, Sjögren’s syndrome, bone losson April 14, 2020 at 5:00 pm
The absence of tristetraprolin (TTP), a protein critical to the control of inflammation, leads to rapid and severe bone loss, UB researchers recently discovered. Now, with the support of a 5-year, $2 ...
- What’s the Difference Between Osteoporosis and Osteoarthritis?on January 30, 2020 at 7:52 am
In addition medications may be recommended that reduce bone loss or help build bone. Often patients are prescribed a medication to decrease bone breakdown and then another to stimulate bone formation.
via Bing News